Evaluating the association between radiomic features on breast MRI and dormant tumor cell presence in the SURMOUNT trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Epidemiologic risk factors associated with breast cancer subtypes. Frequency of L858R and D746-750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by ...
Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...
Dual anti–human epidermal growth factor receptor 2 (HER2) therapy plus chemotherapy followed by maintenance treatment with HER2-targeted and endocrine therapies is standard first-line treatment for ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its ...
“Neoadjuvant treatment with 12 weeks of THP led to a pCR rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer at the time of surgery, compared to 33% for those with ...
Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...
Hosted on MSN
Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients
Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results